Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
SUMMARY Kidney cancer, one of the ten most prevalent malignancies in the world, has exhibited increased incidence over the last decade. The most common subtype is “clear cell” renal cell carcinoma (ccRCC), which features consistent metabolic abnormalities, such as highly elevated glycogen and lipid deposition. By integrating metabolomic, genomic, and transcriptomic data, we determined that enzymes in multiple metabolic pathways are universally depleted in human ccRCC tumors, which are otherwise genetically heterogeneous. Notably, the expression of key urea cycle enzymes, including arginase 2 (ARG2) and argininosuccinate synthase 1 (ASS1), is strongly repressed in ccRCC. Reduced ARG2 activity promotes ccRCC tumor growth through at least two distinct mechanisms: conserving the critical biosynthetic cofactor pyridoxal phosphate, and avoiding toxic polyamine accumulation. Pharmacological approaches to restore urea cycle enzyme expression would greatly expand treatment strategies for ccRCC patients, where current therapies only benefit a subset of those afflicted with renal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Apart from VHL loss, ccRCC exhibits remarkable genetic heterogeneity (Gerlinger et al., 2012).”
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 3×
“Consequently, pharmacological inhibition of specific metabolic pathways may preferentially limit tumor cell growth and proliferation, and multiple metabolism-based therapies are currently in development (Pavlova and Thompson, 2016; Vander Heiden and DeBerardinis, 2017; Yen et al., 2017).”
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · cited 6×
“Recent large-scale analyses identified frequent mutations in three genes, PBRM1 ( 40%), SETD2 ( 15%), and BAP1 ( 15%), all of which encode epigenetic regulators and reside in a 43 Mb region on chromosome 3p that encompasses VHL (Dalgliesh et al., 2010; Peña-Llopis et al., 2012; Sato et al., 2013; Cancer Genome Atlas…”
InfluentialFundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 1×
“For example, enhanced glycolysis, first reported by Otto Warburg in the 1920s, provides a broad array of biosynthetic precursors required for the generation of amino acids, lipids, nucleotides, NADPH, and other biochemical intermediates (DeBerardinis and Chandel, 2016; Pavlova and Thompson, 2016).”
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 1×
“By expressing a constitutively active form of RagB, RagB Q99L (RagB), which confers high levels of mTORC1 activity (Sancak et al., 2008) even in the absence of amino acids (see Figure S4G), we also examined whether ARG2 instead modulates mTORC1 through global changes in amino acid availability.”
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“In VHL-deficient ccRCCs, constitutive HIF expression reprograms cellular metabolism and induces tumor angiogenesis, primarily through activation of downstream HIF target genes (Majmundar et al., 2010).”
Self-citationL-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Self-citationBirsoy, K., Wang, T., Chen, W. W., Freinkman, E., Abu-Remaileh, M., & Sabatini, D. M. (2015) · Cell · doi:10.1016/j.cell.2015.07.016 · Cited by 1,388
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173 · cited 9×
“Recent large-scale analyses identified frequent mutations in three genes, PBRM1 ( 40%), SETD2 ( 15%), and BAP1 ( 15%), all of which encode epigenetic regulators and reside in a 43 Mb region on chromosome 3p that encompasses VHL (Dalgliesh et al., 2010; Peña-Llopis et al., 2012; Sato et al., 2013; Cancer Genome Atlas…”
InfluentialSupporting aspartate biosynthesis is an essential function of respiration in proliferating cells
Sullivan, L. B., Gui, D. Y., Hosios, A. M., Bush, L. N., Freinkman, E., & Vander Heiden, M. G. (2015) · Cell · doi:10.1016/j.cell.2015.07.017 · Cited by 1,173
Vinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., Lomas, C., Mendiola, M., Hardisson, D., & Eccles, S. A. (2012) · BMC Biology · doi:10.1186/1741-7007-10-29 · Cited by 1,024
Regulation of mTORC1 by amino acids
Bar-Peled, L., & Sabatini, D. M. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.03.003 · Cited by 773 · cited 1×
“An alternative model posited that ARG2 and ASS1 expression could alter the subcellular distribution of mTORC1, which responds to amino acid stimulation by translocating to the lysosomal surface in a RAG GTPase-dependent manner (Bar-Peled and Sabatini, 2014).”
Kamphorst, J. J., Cross, J. R., Fan, J., de Stanchina, E., Mathew, R., White, E. P., Thompson, C. B., & Rabinowitz, J. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307237110 · Cited by 726
Serine is an essential metabolite for effector T cell expansion
Ma, E. H., Bantug, G., Griss, T., Condotta, S., Johnson, R. M., Samborska, B., Mainolfi, N., Suri, V., Guak, H., Balmer, M. L., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.011 · Cited by 657
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
Li, B., Qiu, B., Lee, D. S. M., Walton, Z. E., Ochocki, J. D., Mathew, L. K., Mancuso, A., Gade, T. P. F., Keith, B., Nissim, I., et al. (2014) · Nature · doi:10.1038/nature13557 · Cited by 535 · cited 8×
“ccRCC Distinguished by Loss of Urea Cycle Enzymes We employed metabolic gene set and direct metabolomics analyses of matched human ccRCC tumor and adjacent healthy kidney samples to identify the most significantly suppressed metabolic pathways in renal cancers (Li et al., 2014).”
InfluentialSelf-citationAG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Yen, K., Travins, J., Wang, F., David, M. D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1034 · Cited by 471
Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene
Shen, C., Beroukhim, R., Schumacher, S. E., Zhou, J., Chang, M., Signoretti, S., & Kaelin, W. G. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0098 · Cited by 413
Nutrient acquisition strategies of mammalian cells
Palm, W., & Thompson, C. B. (2017) · Nature · doi:10.1038/nature22379 · Cited by 388 · cited 1×
“While metabolic adaptations supporting tumor cell growth and division have been extensively studied (Palm and Thompson, 2017; Vander Heiden and DeBerardinis, 2017), global metabolic shifts contributing to tumor cell survival remain less clear (Kamphorst et al.”
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis
Rabinovich, S., Adler, L., Yizhak, K., Sarver, A., Silberman, A., Agron, S., Stettner, N., Sun, Q., Brandis, A., Helbling, D., et al. (2015) · Nature · doi:10.1038/nature15529 · Cited by 382 · cited 5×
“demonstrated that ASS1 deficiency increases cytoplasmic aspartate levels (Rabinovich et al., 2015), which are critical for maintaining pyrimidine biosynthesis in multiple cancer cell lines (Birsoy et al.”
InfluentialCPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
Kim, J., Hu, Z., Cai, L., Li, K., Choi, E., Faubert, B., Bezwada, D., Rodriguez-Canales, J., Villalobos, P., Lin, Y.-F., et al. (2017) · Nature · doi:10.1038/nature22359 · Cited by 325
Khaitan, D., Chandna, S., Arya, M., & Dwarakanath, B. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-12 · Cited by 196
Biosynthesis of polyamines and polyamine-containing molecules
Michael, A. J. (2016) · Biochemical Journal · doi:10.1042/bcj20160185 · Cited by 180 · cited 2×
“Ornithine-derived putrescine is converted to higher-order polyamines spermidine and spermine through the addition of decarboxy-SAM-derived aminopropyl groups (Michael, 2016) (Figure 6A).”
Yoon, C., Shim, Y., Kim, E., Lee, J., Won, N., Kim, J., Park, I., Yoon, D., & Min, B. (2007) · International Journal of Cancer · doi:10.1002/ijc.22322 · Cited by 165 · cited 2×
“While metabolic adaptations supporting tumor cell growth and division have been extensively studied (Palm and Thompson, 2017; Vander Heiden and DeBerardinis, 2017), global metabolic shifts contributing to tumor cell survival remain less clear (Kamphorst et al., 2013; Young et al., 2013).”
ATM Couples Replication Stress and Metabolic Reprogramming during Cellular Senescence
Aird, K. M., Worth, A. J., Snyder, N. W., Lee, J. V., Sivanand, S., Liu, Q., Blair, I. A., Wellen, K. E., & Zhang, R. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.014 · Cited by 113
Self-citation
Cited by
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
Metabolic programming and immune suppression in the tumor microenvironment
Arner, E. N., & Rathmell, J. C. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.009 · Cited by 668
Myeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzynska, Z., Jasinski, M., Nowis, D., & Golab, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 424
Rewiring urea cycle metabolism in cancer to support anabolism
Keshet, R., Szlosarek, P., Carracedo, A., & Erez, A. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0054-z · Cited by 323
Arginine reprograms metabolism in liver cancer via RBM39
Mossmann, D., Müller, C., Park, S., Ryback, B., Colombi, M., Ritter, N., Weißenberger, D., Dazert, E., Coto-Llerena, M., Nuciforo, S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.09.011 · Cited by 293
Metadata
- Authors
- Ochocki, J. D., Khare, S., Hess, M., Ackerman, D., Qiu, B., Daisak, J. I., Worth, A. J., Lin, N., Lee, P., Xie, H., Li, B., Wubbenhorst, B., Maguire, T. G., Nathanson, K. L., Alwine, J. C., Blair, I. A., Nissim, I., Keith, B., & Simon, M. C.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 27
- Issue
- 6
- Pages
- 1263-1280.e6
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2802759810
- Cited by
- 130
- References
- 26
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.